Eisai To Try New Dosing sNDA For Dacogen
This article was originally published in The Pink Sheet Daily
Executive Summary
Celgene’s Vidaza could take over MDS market after Dacogen’s Phase III failure, analysts say.
You may also be interested in...
Celgene Awaits FDA Nod To Relaunch Vidaza With Survival Labeling
Move capitalizes on failure of Eisai’s Dacogen to show a survival benefit in elderly MDS patients.
Celgene Awaits FDA Nod To Relaunch Vidaza With Survival Labeling
Move capitalizes on failure of Eisai’s Dacogen to show a survival benefit in elderly MDS patients.
Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition
MGI sale comes less than two weeks after the biopharma said it was exploring "strategic alternatives."